Precision Cancer Therapy Driving Investment and Innovation Antibody-drug conjugates (ADCs) are rapidly emerging as a transformative force in precision medicine, revolutionizing cancer treatment by combining the targeting precision of monoclonal…
Executive Summary – The FDA’s Accelerated Approval (AA) pathway has been instrumental inexpediting treatments for serious conditions, but recent scrutiny,…
KYBORA, a leading global advisory firm specializing in biopharma transactions, served as the exclusiveadvisor to Xbrane Biopharma AB (Nasdaq Stockholm:…